vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and CaliberCos Inc. (CWD). Click either name above to swap in a different company.
CaliberCos Inc. is the larger business by last-quarter revenue ($4.1M vs $2.5M, roughly 1.7× Bolt Biotherapeutics, Inc.). CaliberCos Inc. runs the higher net margin — -188.3% vs -265.2%, a 76.9% gap on every dollar of revenue. Over the past eight quarters, Bolt Biotherapeutics, Inc.'s revenue compounded faster (-31.2% CAGR vs -57.6%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.
BOLT vs CWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $4.1M |
| Net Profit | $-6.6M | $-7.7M |
| Gross Margin | — | — |
| Operating Margin | -283.4% | -196.6% |
| Net Margin | -265.2% | -188.3% |
| Revenue YoY | — | -52.5% |
| Net Profit YoY | 58.4% | 32.2% |
| EPS (diluted) | $-9.38 | $1.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $4.1M | ||
| Q3 25 | $2.2M | $3.6M | ||
| Q2 25 | $1.8M | $5.1M | ||
| Q1 25 | $1.2M | $7.3M | ||
| Q4 24 | $0 | $8.7M | ||
| Q3 24 | $1.1M | $11.3M | ||
| Q2 24 | $1.3M | $8.2M | ||
| Q1 24 | $5.3M | $23.0M |
| Q4 25 | $-6.6M | $-7.7M | ||
| Q3 25 | $-7.1M | $-4.4M | ||
| Q2 25 | $-8.6M | $-5.3M | ||
| Q1 25 | $-11.0M | $-4.4M | ||
| Q4 24 | $-15.9M | $-11.4M | ||
| Q3 24 | $-15.2M | $146.0K | ||
| Q2 24 | $-21.2M | $-4.7M | ||
| Q1 24 | $-10.8M | $-3.8M |
| Q4 25 | -283.4% | -196.6% | ||
| Q3 25 | -355.1% | -129.6% | ||
| Q2 25 | -510.5% | -112.4% | ||
| Q1 25 | -991.4% | -62.7% | ||
| Q4 24 | — | -236.8% | ||
| Q3 24 | -1441.1% | 0.0% | ||
| Q2 24 | -1772.3% | -65.0% | ||
| Q1 24 | -324.1% | -22.9% |
| Q4 25 | -265.2% | -188.3% | ||
| Q3 25 | -329.4% | -120.2% | ||
| Q2 25 | -474.6% | -104.5% | ||
| Q1 25 | -903.4% | -60.7% | ||
| Q4 24 | — | -247.6% | ||
| Q3 24 | -1330.1% | 1.3% | ||
| Q2 24 | -1662.4% | -57.8% | ||
| Q1 24 | -205.0% | -16.6% |
| Q4 25 | $-9.38 | $1.95 | ||
| Q3 25 | $-3.72 | $-1.65 | ||
| Q2 25 | $-4.46 | $-4.15 | ||
| Q1 25 | $-0.29 | $-3.85 | ||
| Q4 24 | $-13.73 | $-10.15 | ||
| Q3 24 | $-7.93 | $0.12 | ||
| Q2 24 | $-11.12 | $-4.34 | ||
| Q1 24 | $-0.28 | $-3.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $1.3M |
| Total Assets | $56.7M | $135.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $2.9M | ||
| Q3 25 | $31.9M | $10.9M | ||
| Q2 25 | $34.8M | $683.0K | ||
| Q1 25 | $38.8M | $1.6M | ||
| Q4 24 | $47.3M | $2.3M | ||
| Q3 24 | $53.8M | $1.6M | ||
| Q2 24 | $73.7M | $1.8M | ||
| Q1 24 | $91.3M | $2.1M |
| Q4 25 | $26.5M | $1.3M | ||
| Q3 25 | $32.1M | $4.2M | ||
| Q2 25 | $38.8M | $-19.9M | ||
| Q1 25 | $46.8M | $-15.8M | ||
| Q4 24 | $57.2M | $-12.6M | ||
| Q3 24 | $72.0M | $-3.8M | ||
| Q2 24 | $85.9M | $-4.7M | ||
| Q1 24 | $104.2M | $-745.0K |
| Q4 25 | $56.7M | $135.4M | ||
| Q3 25 | $65.1M | $82.6M | ||
| Q2 25 | $75.5M | $59.3M | ||
| Q1 25 | $85.9M | $103.6M | ||
| Q4 24 | $99.6M | $105.5M | ||
| Q3 24 | $109.3M | $158.6M | ||
| Q2 24 | $124.2M | $195.2M | ||
| Q1 24 | $142.9M | $201.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-12.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-12.1M | ||
| Q3 25 | $-9.7M | $-4.6M | ||
| Q2 25 | $-9.6M | $-1.2M | ||
| Q1 25 | $-13.4M | $-1.7M | ||
| Q4 24 | $-14.4M | $555.0K | ||
| Q3 24 | $-14.0M | $-74.0K | ||
| Q2 24 | $-16.1M | $1.4M | ||
| Q1 24 | $-16.8M | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1227.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.51× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
